LLM Dergi最新文献

{"title":"İkinci Allojenik Kök Hücre Nakli: Gerçek Yaşam Verisi","authors":"Ekin Kırcalı, Güldane Cengiz Seval, Cemal Öztürk, Hülya Yılmaz, Mustafa Can Şenoymak, Gül Yavuz Ermiş, Sinem Civriz Bozdağ, Meltem Kurt Yüksel, Pervin Topçuoğlu, Önder Arslan, Taner Demirer, Osman İlhan, Günhan Gürman, Meral Beksaç, Selami Koçak Toprak","doi":"10.5578/llm.20229804","DOIUrl":"https://doi.org/10.5578/llm.20229804","url":null,"abstract":"","PeriodicalId":354438,"journal":{"name":"LLM Dergi","volume":"32 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121361688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Otolog Kök Hücre Transplantasyonunda Sitomegalovirüs (CMV) ve Hepatit B (HBV) Reaktivasyonu: Tek Merkez Deneyimi","authors":"A. Gemici, Hüseyin Saffet Beköz, Ö. G. Sevindik, Sevil Sadri, İstemi Serin, Vedat Buğra Erol, F. Sargın, Leylagül Kaynar","doi":"10.5578/llm.20229802","DOIUrl":"https://doi.org/10.5578/llm.20229802","url":null,"abstract":"Objective: Cytomegalovirus (CMV) reactivation is a frequently encountered clinical condition during allogeneic hematopoietic stem cell transplantation. Hepatitis B reactivation (HBV) can occur asymptomatically only with re-emergence or increase in blood HBV-DNA levels, as well as in different clinical manifestations, including acute hepatitis and fulminant liver failure. While allogeneic hematopoietic stem cell transplantation is an independent risk factor, the risk for autologous hematopoietic stem cell (HSC) recipients and its effects on the transplantation statistically significantly higher than the patient group without CMV reactivation. Conclusion: Autologous stem cell transplantation also constitutes an important type of treatment to be careful in terms of viral reactivation.","PeriodicalId":354438,"journal":{"name":"LLM Dergi","volume":"31 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126787611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pediyatrik Kanser Hastalarında Otolog Kök Hücre Toplama İşlemine Etki Eden Faktörlerin Değerlendirilmesi","authors":"K. Yalçın, Ersin Erhal, Melihşah Yıldırım, Burcu Kömoğ, Suna Çelen, Suleimen Zhumatayev, Nargiz Azizova Gurbanzade, Gulsun Karasu, A. Yeşilipek","doi":"10.5578/llm.20229902","DOIUrl":"https://doi.org/10.5578/llm.20229902","url":null,"abstract":"Objective: Pediatric cancer patients comprise a fragile patient group regarding age and intensive therapy. It is known that factors like apheresis machine, characteristics of patients, primary disease, and cellular parameters before the process impact the efficacy of stem cell apheresis. In this study, we aim to evaluate the characteristic features of stem cell apheresis and the influencing factors of the process. Patients and Methods: This study involves 42 patients who received a total of 88 aphereses, between August 2012-March 2021in our pediatric stem cell transplantation unit. All of the patients received chemotherapy and GCSF for mobilization. The patients received plerixafor in case of unsuccessful mobilization. Results: For most of the patients (n= 23, 55%), targeted cell numbers could be reached on the second day of apheresis. Especially the patients with neuroblastoma and lymphoma need to have more than one apheresis. Our results indicate that median MNC and CD 34 + cell counts before the apheresis were significantly associated with successful apheresis (p< 0.01 and p= 0.03 respectively). Regarding the influence of primary disease, we showed that successful apheresis was less in neuroblastoma and lymphoma compared to other pediatric cancers (p= 0.01). We reported successful apheresis with plerixafor for six patients who had unsuccessful apheresis before. Conclusion: In this study, it is shown that median MNC counts before apheresis, median CD 34 + cell counts before apheresis, and primary disease are influencing factors for successful apheresis. This study indicates that plerixafor may enhance the apheresis efficacy even in unsuccessful apheresis attempts with standard mobilization protocol. Identifying the influencing factors on apheresis for such a fragile patient population may help the procedure to be more efficient and safe for the children.","PeriodicalId":354438,"journal":{"name":"LLM Dergi","volume":"31 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123532091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Çoklu İlaca Dirençli Akut Graft Versus Host Hastalığında Ruksolitinib","authors":"Özlen Bektaş, Osman Akıdan, Merve Kestane, Nergiz Erkut, Bircan Sönmez, Mehmet Sönmez","doi":"10.5578/llm.20229901","DOIUrl":"https://doi.org/10.5578/llm.20229901","url":null,"abstract":"Objective: Graft versus host disease (GvHD) is the most important cause of morbidity and mortality in allogeneic stem cell transplantation (Allo-SCT). Ruxolitinib is an oral Janus Kinase (JAK) 1/2 inhibitor and is effective in treatment resistant GvHD. Patients and Methods: Eighteen patients with GVHD on ruxolitinib treatment during 2018- 2020 in Karadeniz Technical University Hematology department were evaluated retrospectively. Results: Median time to first response of ruxolitinib was 0.5 months (0.5-0.7) and overall response time was 2.3 months (0.8-7.8) (IQR). The response rate on 28th day was 61.1%. Overall survival was 2.5 months (1.2-10.1) in which 3.4 months (2-16.5) in the group of ruxolitinib responders and 1.1 months (0.8-2.5) (IQR) in the group of ruxolitinib non responsers. In ruxolitinib responders, 8 patients (66.7%) were alive and, 4 patients (33.3%) were dead while in nonresponders 6 patients (100%) were dead (p= 0.013). The overall survival was significantly higher in those with VGPR compared with those who did not (p= 0.001). Bacteremia developed in 7 patients (%38.9), and 6 o these were unresponsive to ruxolitinib treatment. Conclusion: Ruxolitinib is safe and effective in multidrug resistant aGvHH. Deaths due to bacteremia and sepsis occur less frequently in patients who respond to treatment, thus prolonging survival. The depth of tretment response in GvHH is a very important determination of long term survival.","PeriodicalId":354438,"journal":{"name":"LLM Dergi","volume":"2 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122649711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Marjinal Zon Lenfoma Tanılı Hastalarda Klinik Özellikler ve Olası Prognostik Faktörler: İki Merkezden Retrospektif Analiz","authors":"Pınar Tığlıoğlu, Abdulkerim Yıldız, Murat Albayrak, Mesut Tığlıoğlu, Buğra Sağlam, Senem Maral, Hacer Berna Afacan Öztürk, Meltem Aylı, Osman Şahin, Murat Yıldırım","doi":"10.5578/llm.20229903","DOIUrl":"https://doi.org/10.5578/llm.20229903","url":null,"abstract":"Objective: Marginal zone lymphoma accounts 5%-17% of all non-Hodgkin lymphomas and has an indolent clinical course. The parameters that predict prognosis and the need for treatment are still unclear. The aim of the current study was to examine the impact of parameters on the course of disease and the need for treatment in marginal zone lymphoma. Patients and Methods: A retrospective study was conducted with marginal zone lymphoma patients in the hematology departments of two centres between 2010 and 2018. The demographic and disease characteristics, and also hematological and biochemical parameters at the time of diagnosis were examined. The effect of the parameters on overall survival and need for treatment were analyzed. Fourty patients were included in this study. Results: A total of 40 MZL patients, 25 (62.5%) women and 15 (37.5%) men, were evaluated. During the follow-up, 25 patients required treatment and 15 patiens were followed up without treatment. overall survival of all marginal zone lymphoma patients was 58.4 months. Overall survival was significantly higher in patients with nodal marginal zone lymphoma than in extranodal and splenic marginal zone lymphoma patients. The platelet count of untreated patients at the time of diagnosis were significantly higher than patients who received treatment (p= 0.04). Conclusion: We demonstrated platelet count at the time of diagnosis as a predictive factor for future treatment need. It is an objective and simple blood test that may be helpful to predict the course of the disease although further studies are warranted.","PeriodicalId":354438,"journal":{"name":"LLM Dergi","volume":"10 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128537678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relaps/Refrakter Akut Lenfoblastik Lösemide İnotuzumab Ozogamisin Tedavisi Sonrası Allojenik Kök Hücre Nakli Sonuçları","authors":"Uğur Şahin, Ender Soydan, Selin Merih Urlu, Mevlüde Kurdal Okcu, Ozan Özkumur, Şahika Şen, Ayla Gökmen","doi":"10.5578/llm.20229904","DOIUrl":"https://doi.org/10.5578/llm.20229904","url":null,"abstract":"Objective: The prognosis of relapsed/refractory ALL (R/R ALL) in adults is dismal. Allogeneic hematopoietic stem cell transplantation (ASCT) is the only available curative treatment option in R/R ALL. The primary aim of salvage treatments is to provide the deepest disease control, while creating a safe bridge to ASCT. Monotherapy with Inotuzumab ozogamycin (InO) has been reported to provide deep treatment responses at a high rate, as well as enabling for ASCT four times higher than standard chemotherapies. This study summarizes the outcomes of R/R ALL patients who underwent ASCT in our center after receiving InO salvage therapy. Patients and Methods: R/R ALL patients who underwent ASCT in our center between January 2018 and January 2021 after achieving remission with InO salvage were retrospectively evaluated. Results: A total of six patients, three of whom were male, with a median age of 40 (19-71) at the time of ASCT were included. Two patients received InO treatment before the second or third ASCT, while the remaining four before the first. A median of two courses (1-4) of InO was administered. No serious adverse events were observed during treatment with InO. Venoocclusive disease prophylaxis with defibrotide was given to 83.3% (n= 5) of the patients during ASCT. Transplant-related mortality was observed in 50% (n= 3), and mortality due to early disease progression (central nervous system involvement) was observed in 16.7% (n= 1) of patients. Overall survival tended to be lower in patients receiving more than two courses of InO (p= 0.10, by log-rank test). Of the patients 33.3% (n= 2) are in complete remission (CR) within a median follow-up of 28 months (8-47) without any transplant-related complications. Conclusion: Long-term survival is possible in R/R ALL with ASCT after obtaining CR via InO salvage. More than two cycles of InO before ASCT should be avoided as it increases transplant-related early mortality. Venooclusive disease, reported as the most important cause of early mortality, was not observed in this study.","PeriodicalId":354438,"journal":{"name":"LLM Dergi","volume":"17 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126777412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relaps/Refrakter Lenfoma (Mantle Hücreli Lenfoma Hariç) Hastalarında Lenalidomid Bazlı Tedavi Sonuçları: Çok Merkezli Sonuçlar","authors":"M. Doğu, İstemi Serin, A. Gemici, Abdülkadir Karışmaz, Burhan Turgut","doi":"10.5578/llm.20219602","DOIUrl":"https://doi.org/10.5578/llm.20219602","url":null,"abstract":"","PeriodicalId":354438,"journal":{"name":"LLM Dergi","volume":"34 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"117061300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Süt Çocuklarında Akut Lenfoblastik Lösemi: Geriye Dönük Tek Merkez Deneyimi","authors":"Sibel Akpınar Tekgündüz, Gönül Aydoğan, Cengiz Bayram, Gülsün Özdemir, Ezgi Paslı Uysalol, Şadan Hacısalihoğlu, Esra Arslantaş, Ali Ayçiçek","doi":"10.5578/llm.20219604","DOIUrl":"https://doi.org/10.5578/llm.20219604","url":null,"abstract":"","PeriodicalId":354438,"journal":{"name":"LLM Dergi","volume":"74 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133245418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Non-Hodgkin Lenfomalı Hastalarda Hepatit B Prevalansının Değerlendirilmesi ve Profilaksinin Yeri","authors":"Müzeyyen Aslaner Ak, Birsen Sahip","doi":"10.5578/llm.20219601","DOIUrl":"https://doi.org/10.5578/llm.20219601","url":null,"abstract":"","PeriodicalId":354438,"journal":{"name":"LLM Dergi","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130821346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"İnvaziv Duktal Meme Karsinomu Tedavisi Sonrası Gelişen Akut Myeloid Lösemi","authors":"Z. Güven, Serhat Çelik, Muzaffer Keklik, Ali Ünal, Leylagül Kaynar","doi":"10.5578/llm.20219603","DOIUrl":"https://doi.org/10.5578/llm.20219603","url":null,"abstract":"","PeriodicalId":354438,"journal":{"name":"LLM Dergi","volume":"10 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115000160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}